Free Trial

Perspective Therapeutics (CATX) Competitors

Perspective Therapeutics logo
$3.42 +0.04 (+1.24%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CATX vs. PLSE, INMD, IRMD, BBNX, EMBC, KMTS, TNDM, AXGN, SIBN, and BVS

Should you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Beta Bionics (BBNX), Embecta (EMBC), Kestra Medical Technologies (KMTS), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.

Perspective Therapeutics vs. Its Competitors

Perspective Therapeutics (NYSE:CATX) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by company insiders. Comparatively, 74.6% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Perspective Therapeutics presently has a consensus target price of $12.56, suggesting a potential upside of 266.91%. Pulse Biosciences has a consensus target price of $22.00, suggesting a potential upside of 51.79%. Given Perspective Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Perspective Therapeutics is more favorable than Pulse Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perspective Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.18
Pulse Biosciences
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Perspective Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Pulse Biosciences has a net margin of 0.00% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Perspective Therapeutics-4,096.66% -27.40% -23.16%
Pulse Biosciences N/A -63.19%-54.98%

In the previous week, Pulse Biosciences had 2 more articles in the media than Perspective Therapeutics. MarketBeat recorded 5 mentions for Pulse Biosciences and 3 mentions for Perspective Therapeutics. Pulse Biosciences' average media sentiment score of 1.08 beat Perspective Therapeutics' score of -0.20 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perspective Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pulse Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perspective TherapeuticsN/AN/A-$46.51MN/AN/A
Pulse BiosciencesN/AN/A-$53.58M-$1.05-13.80

Summary

Perspective Therapeutics beats Pulse Biosciences on 7 of the 13 factors compared between the two stocks.

Get Perspective Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CATX vs. The Competition

MetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$255.09M$81.33M$5.82B$21.54B
Dividend YieldN/AN/A5.69%3.53%
P/E RatioN/A11.5474.6729.80
Price / SalesN/A113.20454.5451.04
Price / CashN/A18.4137.0824.52
Price / Book1.2810.9812.184.59
Net Income-$46.51M-$26.48M$3.29B$1.00B
7 Day Performance-1.10%5.66%1.08%0.80%
1 Month Performance-14.02%3.86%7.32%4.79%
1 Year Performance-78.40%87.95%63.11%16.13%

Perspective Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CATX
Perspective Therapeutics
1.7335 of 5 stars
$3.42
+1.2%
$12.56
+266.9%
-78.4%$255.09MN/A0.0070
PLSE
Pulse Biosciences
4.1347 of 5 stars
$15.11
-0.4%
$22.00
+45.6%
-11.9%$1.02B$700K-14.39140Positive News
INMD
InMode
3.0559 of 5 stars
$14.98
+4.0%
$18.04
+20.4%
-9.2%$946.89M$394.82M6.06480Positive News
IRMD
iRadimed
4.8063 of 5 stars
$71.99
-0.2%
$72.00
+0.0%
+58.9%$915.71M$73.24M44.44110Positive News
Short Interest ↓
BBNX
Beta Bionics
1.0921 of 5 stars
$20.20
+0.5%
$22.56
+11.7%
N/A$878.09M$65.12M0.00294
EMBC
Embecta
4.5122 of 5 stars
$14.96
+3.2%
$19.00
+27.0%
-1.7%$875.01M$1.12B10.462,100Positive News
KMTS
Kestra Medical Technologies
1.609 of 5 stars
$17.00
+3.0%
$27.33
+60.8%
N/A$872.95M$59.81M0.00300News Coverage
Positive News
Gap Up
TNDM
Tandem Diabetes Care
4.4939 of 5 stars
$12.58
+1.5%
$22.47
+78.6%
-70.1%$850.03M$940.20M-4.072,650Positive News
AXGN
AxoGen
2.8944 of 5 stars
$15.98
+3.8%
$26.00
+62.7%
+26.5%$735.24M$187.34M-159.78450Positive News
SIBN
SiBone
3.7856 of 5 stars
$16.29
-0.4%
$23.67
+45.3%
+8.2%$702.75M$167.18M-29.09350Positive News
BVS
Bioventus
1.0138 of 5 stars
$7.19
+1.3%
N/AN/A$594.47M$573.28M14.081,200

Related Companies and Tools


This page (NYSE:CATX) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners